CompletedNot Applicable

Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy

China222 participantsStarted 2024-01-01

Plain-language summary

This retrospective cohort study aims to evaluate the clinical efficacy and safety of mavacamten in adult patients with obstructive hypertrophic cardiomyopathy (oHCM). A total of 222 patients were included and categorized based on treatments received in routine clinical practice into a mavacamten group and a standard therapy group. The primary outcome is the change in resting left ventricular outflow tract (LVOT) gradient at Week 30. Secondary outcomes include changes in Valsalva LVOT gradient, New York Heart Association (NYHA) functional class, cardiac biomarkers, and echocardiographic parameters. Safety outcomes include adverse events and left ventricular systolic dysfunction. This study provides real-world evidence on the effectiveness and safety of mavacamten in Chinese patients with oHCM.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years * Diagnosis of hypertrophic cardiomyopathy * NYHA functional class II-III * First-time treatment with mavacamten Exclusion Criteria: * Known hypersensitivity to mavacamten or its components * Left ventricular ejection fraction (LVEF) \<55% * Septal reduction therapy within 6 months prior to enrollment * Presence of other conditions requiring long-term anticoagulation * Pregnancy or breastfeeding * Any condition deemed unsuitable by the investigator

What they're measuring

Change in Resting Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30

Timeframe: Baseline to Week 30

Trial details

NCT IDNCT07529938

SponsorChinese Academy of Medical Sciences, Fuwai Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-05-30